HCC患者RFA后索拉非尼:一项初步研究。

Hepato-gastroenterology Pub Date : 2015-03-01
Giorgio de Stefano, Nunzia Farella, Umberto Scognamiglio, Giulia Liorre, Giosuele Calabria, Tiziana Ascione, Antonio Giorgio, Valentina Iodice
{"title":"HCC患者RFA后索拉非尼:一项初步研究。","authors":"Giorgio de Stefano,&nbsp;Nunzia Farella,&nbsp;Umberto Scognamiglio,&nbsp;Giulia Liorre,&nbsp;Giosuele Calabria,&nbsp;Tiziana Ascione,&nbsp;Antonio Giorgio,&nbsp;Valentina Iodice","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aims: </strong>To investigate the effectiveness and safety of sorafenib after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).</p><p><strong>Methodology: </strong>44 intermediate or advanced HCC patients received sorafenib treatment after debulking with RFA therapy. Time to progression (TTP), response rate (RR), duration of sorafenib treatment and adverse effects were evaluated. An explorative comparison was performed with patients treated with sorafenib only.</p><p><strong>Results: </strong>At 12 months, TTP was 10.3 months (range: 1-32). RR was 61% with 2 complete responses, and duration of sorafenib therapy was 10.9 months (1-32). No new safety concerns were report-ed. With sorafenib only, TTP was 7.2 months (range: 0-38) and RR was 40%, with one complete response; duration of therapy was 7.3 months (0-38).</p><p><strong>Conclusions: </strong>The sequence of RFA and sorafenib appears effective and safe in HCC patients. These findings could support the use of a sequential treatment with RFA and sorafenib in HCC patients.</p>","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 138","pages":"261-3"},"PeriodicalIF":0.0000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sorafenib after RFA in HCC patients: a pilot study.\",\"authors\":\"Giorgio de Stefano,&nbsp;Nunzia Farella,&nbsp;Umberto Scognamiglio,&nbsp;Giulia Liorre,&nbsp;Giosuele Calabria,&nbsp;Tiziana Ascione,&nbsp;Antonio Giorgio,&nbsp;Valentina Iodice\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aims: </strong>To investigate the effectiveness and safety of sorafenib after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).</p><p><strong>Methodology: </strong>44 intermediate or advanced HCC patients received sorafenib treatment after debulking with RFA therapy. Time to progression (TTP), response rate (RR), duration of sorafenib treatment and adverse effects were evaluated. An explorative comparison was performed with patients treated with sorafenib only.</p><p><strong>Results: </strong>At 12 months, TTP was 10.3 months (range: 1-32). RR was 61% with 2 complete responses, and duration of sorafenib therapy was 10.9 months (1-32). No new safety concerns were report-ed. With sorafenib only, TTP was 7.2 months (range: 0-38) and RR was 40%, with one complete response; duration of therapy was 7.3 months (0-38).</p><p><strong>Conclusions: </strong>The sequence of RFA and sorafenib appears effective and safe in HCC patients. These findings could support the use of a sequential treatment with RFA and sorafenib in HCC patients.</p>\",\"PeriodicalId\":12985,\"journal\":{\"name\":\"Hepato-gastroenterology\",\"volume\":\"62 138\",\"pages\":\"261-3\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-03-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hepato-gastroenterology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

背景/目的:探讨索拉非尼在肝细胞癌(HCC)患者射频消融(RFA)后的有效性和安全性。方法:44例中晚期HCC患者在RFA降压治疗后接受索拉非尼治疗。评估进展时间(TTP)、缓解率(RR)、索拉非尼治疗持续时间及不良反应。与仅用索拉非尼治疗的患者进行探索性比较。结果:12个月时,TTP为10.3个月(范围:1-32)。RR为61%,2次完全缓解,索拉非尼治疗持续时间为10.9个月(1-32)。没有新的安全隐患报告。单独使用索拉非尼,TTP为7.2个月(范围:0-38),RR为40%,有一次完全缓解;治疗时间7.3个月(0-38)。结论:RFA联合索拉非尼治疗HCC患者有效且安全。这些发现可以支持在HCC患者中使用RFA和索拉非尼的顺序治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Sorafenib after RFA in HCC patients: a pilot study.

Background/aims: To investigate the effectiveness and safety of sorafenib after radiofrequency ablation (RFA) in patients with hepatocellular carcinoma (HCC).

Methodology: 44 intermediate or advanced HCC patients received sorafenib treatment after debulking with RFA therapy. Time to progression (TTP), response rate (RR), duration of sorafenib treatment and adverse effects were evaluated. An explorative comparison was performed with patients treated with sorafenib only.

Results: At 12 months, TTP was 10.3 months (range: 1-32). RR was 61% with 2 complete responses, and duration of sorafenib therapy was 10.9 months (1-32). No new safety concerns were report-ed. With sorafenib only, TTP was 7.2 months (range: 0-38) and RR was 40%, with one complete response; duration of therapy was 7.3 months (0-38).

Conclusions: The sequence of RFA and sorafenib appears effective and safe in HCC patients. These findings could support the use of a sequential treatment with RFA and sorafenib in HCC patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hepato-gastroenterology
Hepato-gastroenterology 医学-外科
自引率
0.00%
发文量
1
审稿时长
1.9 months
期刊介绍: Hepato-Gastroenterology has been discontinued as of 2015. Extremely limited quantities of back issues in print available for sale.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信